Robert Reiter

Dr. Robert Reiter is a distinguished Professor of Urology with a specialization in urologic oncology, particularly known for his expertise in robotic prostatectomy.

His groundbreaking work includes the cloning of the Prostate Stem Cell Antigen and the development of antibodies used in clinical trials for prostate and pancreatic cancer treatments.

Dr. Reiter is a notable figure in the biotechnology industry, having been a founder of Agensys, a company later acquired by Astellas Pharmaceuticals for a substantial amount.

He is also the co-founder of ImaginAb Corp, a biotech firm focusing on engineered antibodies for cancer diagnosis and drug advancement.

Dr. Reiter's educational background includes an MBA in Business from UCLA Anderson School of Management, an MD in Medicine from Stanford University School of Medicine, and a Bachelor of Science in Biology from Yale University.

He has held key positions such as Founder and Chief Medical Officer at ImaginAb, Professor of Urology, Member of the Molecular Biology Institute, and Director of Genitourinary Oncology at UCLA's Jonsson Comprehensive Cancer Center.

During his career, he also served as a Urologic Oncology Fellow at the National Cancer Institute.